DPP4 and cardiovascular disorder: These studies have generally demonstrated that DPP-4 inhibitors do not increase the risk of cardiovascular events, which is an essential consideration when selecting antidiabetic therapy for patients with concurrent renal impairment and cardiovascular disease [87,88].